Lilly's weight-loss pill meets main goal in late-stage sleep apnea study
LLY•Eli Lilly said its oral weight-loss drug Foundayo met the main goal of a late-stage study in obese adults with moderate-to-severe obstructive sleep apnea, reducing breathing interruptions by up to 44% on average at 52 weeks.
1. Study results
Eli Lilly said Foundayo significantly reduced breathing interruptions during sleep in obese adults with moderate-to-severe obstructive sleep apnea, meeting the main goal of a late-stage study. The drug reduced interruptions by up to 44% on average at 52 weeks, measured using a diagnostic scale for sleep apnea severity.
